The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China is a paper indexed in ScholarIQ from OpenAlex.
How many citations does The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China have?
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China has 73 citations in the OpenAlex counts ScholarIQ stores.
When was The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China published?
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China has 2021 year in the ScholarIQ index.
What is the open-access status of The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China?
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China has gold oa status in the ScholarIQ index.
What is the DOI of The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China?
The DOI for The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China is on the source record.
What is the PMID of The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China?
The PMID for The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China is on the source record.
What is the OpenAlex record for The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China?
The OpenAlex for The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China is on the source record.